Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats

Dyskinesia is a serious complication of Parkinson’s disease during levodopa (L-DOPA) treatment. The pathophysiology of L-DOPA-induced dyskinesia (LID) is complex and not fully illuminated. At present, treatment of dyskinesia is quite limited. Recent studies demonstrated neuroinflammation plays an im...

Full description

Bibliographic Details
Main Authors: Chang-Qing Zheng, Hong-Xia Fan, Xiao-Xian Li, Jing-Jie Li, Shuo Sheng, Feng Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.683577/full
id doaj-f4f7db5e13ec4637bc7adcac576403a2
record_format Article
spelling doaj-f4f7db5e13ec4637bc7adcac576403a22021-06-25T05:30:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.683577683577Resveratrol Alleviates Levodopa-Induced Dyskinesia in RatsChang-Qing ZhengHong-Xia FanXiao-Xian LiJing-Jie LiShuo ShengFeng ZhangDyskinesia is a serious complication of Parkinson’s disease during levodopa (L-DOPA) treatment. The pathophysiology of L-DOPA-induced dyskinesia (LID) is complex and not fully illuminated. At present, treatment of dyskinesia is quite limited. Recent studies demonstrated neuroinflammation plays an important role in development of LID. Thus, inhibition of neuroinflammation might open a new avenue for LID treatment. Resveratrol (RES) is the most well-known polyphenolic stilbenoid and verified to possess a large variety of biological activities. DA neurotoxicity was assessed via behavior test and DA neuronal quantification. The movement disorders of dyskinesia were detected by the abnormal involuntary movements scores analysis. Effects of RES on glial cells-elicited neuroinflammation were also explored. Data showed that RES attenuated dyskinesia induced by L-DOPA without affecting L-DOPA’s anti-parkinsonian effects. Furthermore, RES generated neuroprotection against long term treatment of L-DOPA-induced DA neuronal damage. Meanwhile, RES reduced protein expression of dyskinesia molecular markers, ΔFOS B and ERK, in the striatum. Also, there was a strong negative correlation between DA system damage and ΔFOS B level in the striatum. In addition, RES inhibited microglia and astroglia activation in substantia nigra and subsequent inflammatory responses in the striatum during L-DOPA treatment. RES alleviates dyskinesia induced by L-DOPA and these beneficial effects are closely associated with protection against DA neuronal damage and inhibition of glial cells-mediated neuroinflammatory reactions.https://www.frontiersin.org/articles/10.3389/fimmu.2021.683577/fullL-DOPAdyskinesianeuroinflammationresveratrolParkinson disease
collection DOAJ
language English
format Article
sources DOAJ
author Chang-Qing Zheng
Hong-Xia Fan
Xiao-Xian Li
Jing-Jie Li
Shuo Sheng
Feng Zhang
spellingShingle Chang-Qing Zheng
Hong-Xia Fan
Xiao-Xian Li
Jing-Jie Li
Shuo Sheng
Feng Zhang
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
Frontiers in Immunology
L-DOPA
dyskinesia
neuroinflammation
resveratrol
Parkinson disease
author_facet Chang-Qing Zheng
Hong-Xia Fan
Xiao-Xian Li
Jing-Jie Li
Shuo Sheng
Feng Zhang
author_sort Chang-Qing Zheng
title Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
title_short Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
title_full Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
title_fullStr Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
title_full_unstemmed Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
title_sort resveratrol alleviates levodopa-induced dyskinesia in rats
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2021-06-01
description Dyskinesia is a serious complication of Parkinson’s disease during levodopa (L-DOPA) treatment. The pathophysiology of L-DOPA-induced dyskinesia (LID) is complex and not fully illuminated. At present, treatment of dyskinesia is quite limited. Recent studies demonstrated neuroinflammation plays an important role in development of LID. Thus, inhibition of neuroinflammation might open a new avenue for LID treatment. Resveratrol (RES) is the most well-known polyphenolic stilbenoid and verified to possess a large variety of biological activities. DA neurotoxicity was assessed via behavior test and DA neuronal quantification. The movement disorders of dyskinesia were detected by the abnormal involuntary movements scores analysis. Effects of RES on glial cells-elicited neuroinflammation were also explored. Data showed that RES attenuated dyskinesia induced by L-DOPA without affecting L-DOPA’s anti-parkinsonian effects. Furthermore, RES generated neuroprotection against long term treatment of L-DOPA-induced DA neuronal damage. Meanwhile, RES reduced protein expression of dyskinesia molecular markers, ΔFOS B and ERK, in the striatum. Also, there was a strong negative correlation between DA system damage and ΔFOS B level in the striatum. In addition, RES inhibited microglia and astroglia activation in substantia nigra and subsequent inflammatory responses in the striatum during L-DOPA treatment. RES alleviates dyskinesia induced by L-DOPA and these beneficial effects are closely associated with protection against DA neuronal damage and inhibition of glial cells-mediated neuroinflammatory reactions.
topic L-DOPA
dyskinesia
neuroinflammation
resveratrol
Parkinson disease
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.683577/full
work_keys_str_mv AT changqingzheng resveratrolalleviateslevodopainduceddyskinesiainrats
AT hongxiafan resveratrolalleviateslevodopainduceddyskinesiainrats
AT xiaoxianli resveratrolalleviateslevodopainduceddyskinesiainrats
AT jingjieli resveratrolalleviateslevodopainduceddyskinesiainrats
AT shuosheng resveratrolalleviateslevodopainduceddyskinesiainrats
AT fengzhang resveratrolalleviateslevodopainduceddyskinesiainrats
_version_ 1721360435528073216